Citations

Clear

2 citation(s) found for "Simpson, Daniel J".

Methylation-associated Gene Expression (MaGE): a non-invasive, in vivo measure of cellular senescence
Simpson, Daniel J , Crofts, Samuel , Mavrommatis, Christos, Suwanlikit, Yossawat , Loyva, Kirstyn, Mielke, Michelle M , Marioni, Riccardo E , Kirschner, Kristina , LeBrasseur, Nathan K , Chandra, Tamir

Mayo Clinic

No container title available | October 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.29.26364335 | PMID 42856468 Get It

Abstract Cellular senescence is a central hallmark of aging, yet its measurement in humans remains invasive, low-throughput and tissue-specific, precluding population-scale study. We developed Methylation-associated Gene Expression (MaGE) predictors: whole-blood DNA methylation proxies of p14 ARF , p16 INK4A and p21 CIP1 expression, plus a composite score, providing the first scalable measure of senescence-marker expression. Deployed across Generation Scotland (n=18,859), MaGE yielded 45 Bonferroni-significant associations spanning 18 incident diseases and all-cause mortality. The two strongest associations recapitulated the established tissue specificity of p21 CIP1 and p16 INK4A activation, with MaGE-p21 associating with incident alcoholic liver disease and MaGE-p16 with pulmonary fibrosis. In a separate study, MaGE tracked disease severity and treatment response in Crohn’s disease. MaGE is a scalable, interpretable biomarker of senescence that enables its study at population scale and offers a route to patient stratification in senolytic trials.
Thermal ablation compared to stereotactic body radiation therapy for hepatocellular carcinoma: A multicenter retrospective comparative study
Kim, Hannah P. , Singal, Amit G. , Owen, Dawn , Parikh, Neehar D. , Rose, Steven C., McGinty, Katrina , Agala, Chris B. , Burke, Lauren M. , Abate, Anjelica, Do, John, Folkert, Michael R. , Forbes, C.D., Hattangadi‐Gluth, Jona A. , Hayashi, Paul H. , Jones, Keri, Lawrence, Theodore S. , Maurino, C. , Mayo, Charles S. , Pak, Taemee , Patil, Preethi, Simpson, Daniel R. , Tepper, Joel E. , Thapa, Diwash , Moon, Andrew M , Singal, Amit , Owen, Dawn , Parikh, Neehar D , McGinty, Katrina A , Burke, Lauren M , Altun, Ersan , Folkert, Michael R , Hayashi, Paul H , Khatri, Gaurav , Kono, Yuko , Lawrence, Theodore S , Tepper, Joel E , Gerber, David A , Mendiratta-Lala, Mishal , Beyer, Christian, Forbes, Chalon, Khatri, Gaurav , Mauro, David M. , Sanders, Emily C. , Yanagihara, Ted K. , Wang, Kyle , Gerber, David A.

Mayo Clinic

Hepatology Communications | June 14, 2023 | Volume: 7 | Issue: 7 | Pages: No page available

10.1097/hc9.0000000000000184 | PMID 37314737 Get It

Background & Aims: Early-stage HCC can be treated with thermal ablation or stereotactic body radiation therapy (SBRT). We retrospectively compared local progression, mortality, and toxicity among patients with HCC treated with ablation or SBRT in a multicenter, US cohort. Approach & Results: We included adult patients with treatment-naïve HCC lesions without vascular invasion treated with thermal ablation or SBRT per individual physician or institutional preference from January 2012 to December 2018. Outcomes included local progression after a 3-month landmark period assessed at the lesion level and overall survival at the patient level. Inverse probability of treatment weighting was used to account for imbalances in treatment groups. The Cox proportional hazard modeling was used to compare progression and overall survival, and logistic regression was used for toxicity. There were 642 patients with 786 lesions (median size: 2.1 cm) treated with ablation or SBRT. In adjusted analyses, SBRT was associated with a reduced risk of local progression compared to ablation (aHR 0.30, 95% CI: 0.15–0.60). However, SBRT-treated patients had an increased risk of liver dysfunction at 3 months (absolute difference 5.5%, aOR 2.31, 95% CI: 1.13–4.73) and death (aHR 2.04, 95% CI: 1.44–2.88, p < 0.0001). Conclusions: In this multicenter study of patients with HCC, SBRT was associated with a lower risk of local progression compared to thermal ablation but higher all-cause mortality. Survival differences may be attributable to residual confounding, patient selection, or downstream treatments. These retrospective real-world data help guide treatment decisions while demonstrating the need for a prospective clinical trial.